$Arcturus Therapeutics(ARCT.US) For a biopharmaceutical company with significant platform value, it's hard to imagine that its stock price would fall below its net cash on hand. Moreover, its COVID-19 vaccine has already been commercialized in Japan and the EU, and its commercialization revenue and future milestone payments are also substantial. Only one of its two mRNA drug pipelines seems to be progressing less than ideally. I just want to say, in the future, someone will surely regret missing out, hahaha, mark my words.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
